Ligand id: 6780

Name: rituximab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: rituximab

Compound class Antibody
Approved drug? Yes (FDA (1997), EMA (1998))
International Nonproprietary Names
INN number INN
7609 rituximab
HSDB 7455 | IDEC-C2B8 | MabThera® | Rituxan®
Rituximab is a type I anti-CD20 monoclonal, designed to target surface CD20 on B-lymphocytes. It is a cancer and autoimmune disease drug.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

NameTrade nameCompanyClinical PhaseIndications
CT-P10; rituximab-abbsBlitzima; Truxima; Tuxella; RitemviaCelltrionApproved (EMA 2017, FDA 2018)Non-Hodgkin lymphoma, chronic lymphocytic leukaemia, granulomatosis with polyangiitis, microscopic polyangiitis and severe rheumatoid arthritis (Truxima only)
PF-05280586 PfizerEvaluated in completed clinical trial NCT01526057 Phase 1/2Rheumatoid arthritis
BCD-020AcellBiaBiocadApproved in 2014 by the Ministry of Health of the Russian Federation; Ph 3 trials elsewhere- see NCT02744196 and NCT01759030 as examplesRheumatoid arthritis
GP2013Rixathon; RiximyoSandozApproved (EMA 2017) non-Hodgkin lymphoma, chronic B-cell lymphocytic leukemia
SAIT101 Archigen BiotechPh 3 comparision clinical trial with MabThera® for follicular lymphoma (NCT02809053), and Ph 1 NCT02819726 for rheumatoid arthritisRheumatoid arthritis, follicular lymphoma
ABP 798 AmgenPh 3 (NCT02747043; NCT02792699)Rheumatoid arthritis, non-Hodgkin lymphoma
BI 695500 Boehringer IngelheimDevelopment halted at Ph 3 (NCT02417129)Non-Hodgkin lymphoma
Database Links
Specialist databases
IMGT/mAb-DB 161
Other databases
GtoPdb PubChem SID 178103386
Immunopaedia Search rituximab
PubChem SID 178103386
Search PubMed clinical trials rituximab
Search PubMed titles rituximab
Search PubMed titles/abstracts rituximab
Wikipedia Rituximab